Silence Therapeutics plc announced that it has completed enrollment in the ALPACAR-360 phase 2 study of zerlasiran (SLN360) in subjects with elevated lipoprotein(a) at high risk of atherosclerotic cardiovascular disease events. The ALPACAR-360 phase 2 study is evaluating approximately 160 subjects with high Lp(a) = 125 nmol/L at high risk of ASCVD events. The primary endpoint is time averaged change in Lp(a) from baseline.

In the phase 1 APOLLO single dose study evaluating healthy volunteers with high Lp(a) = 150 nmol/L, participants who received zerlasiran (300 mg and 600 mg doses) saw median maximal Lp(a) reductions of 96% and 98%, respectively. A further analysis showed median time-averaged reductions during 150 days of follow up exceeded 80% in 300 mg and 600 mg treatment groups. Zerlasiran was well tolerated with no serious safety issues identified.

The Company remains on-track to report topline data from the multiple dose portion of the APOLLO program in the fourth quarter of this year.